Acetylation phenotype status in a Bangladeshi population and its comparison with that of other Asian population data

Biopharmaceutics and Drug Disposition

Volumn 25, Issue 6, 2004, Pages 237-241

  Zaid, Reza B ^a   Nargis, M ^a   Neelotpol, S ^a   Hannan, J M A ^a   Islam, S ^a   Akhter, R ^a   Ali, L ^a   Azad Khan, A K ^a  

^a Bangladesh Institute of Research and Rehabilitation in Diabetes Endocrine and Metabolic Disorders   (Bangladesh)

Author keywords

Acetylator phenotype; Asian; Bangladeshi; Longitude; Sulphadimidine

Indexed keywords

AMONAFIDE; DAPSONE; HYDRALAZINE; ISONIAZID; PROCAINAMIDE; SULFADIMIDINE; SULFONAMIDE; XENOBIOTIC AGENT;

ACETYLATOR PHENOTYPE; ARTICLE; ASIAN; BANGLADESH; CONTROLLED STUDY; CORRELATION ANALYSIS; DATA ANALYSIS; DRUG ACETYLATION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG METABOLISM; DRUG SAFETY; DRUG USE; GEOGRAPHY; HUMAN; METHODOLOGY; PHENOTYPE; POPULATION; PROGNOSIS; REGRESSION ANALYSIS;

ACETYLATION; ACETYLTRANSFERASES; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ASIAN CONTINENTAL ANCESTRY GROUP; BANGLADESH; HUMANS; LINEAR MODELS; MIDDLE AGED; PHENOTYPE; PILOT PROJECTS; SULFANILAMIDES;

EID: 4644338079     PISSN: 01422782     EISSN: None     Source Type: Journal    
DOI: 10.1002/bdd.403     Document Type: Article

References (17)

1. Blum M, Grant DM, McBride W. Human arylamine N-acetyltransferase genes: isolation, chromosomal localization, and functional expression. DNA Cell Biol 1990; 9: 93-203.
2. Hickman D, Risch A, Buckle V. Chromosomal localization of human genes for arylamine N-acetyltransferase. Biochem J 1994; 297: 441-445.
3. Bozkurt A, Basci NE, Kalan S, Tuncer M, Kayaalp SO. N-acetylation phenotyping with sulphadimidine in a Turkish population. Eur J Clin Pharmacol 1990; 38: 53-56.
4. Lil'in ET, Korsunskaia MP, Meksin VA, Drozdov ES, Nazarov VV. [Distribution of acetylator phenotypes in the normal Moscow city population and in chronic alcoholism]. Genetika 1984; 20: 1557-1559.
5. Evans DA, Paterson S, Francisco P, Alvarez G. The acetylator phenotypes of Saudi Arabian diabetics. J Med Genet 1985; 22: 479-483.
6. Evans DA, Wicks J, Higgins J, Assisto M. The acetylator phenotypes of Saudi Arabians with coronary arterial atheroma. J Med Genet 1991; 28: 192-193.
7. Woolhouse NM, Qureshi MM, Bastaki SM, Patel M, Abdulrazzaq Y, Bayoumi RA. Polymorphic N-acetyltransferase (NAT2) genotyping of Emiratis. Pharmacogenetics 1997; 7: 73-82.
8. Zhao B, Lee EJD, Wong JYY. Frequency of mutant CYP1A1, NAT2 and GSTM1 alleles in normal Indians and Malays. Pharmacogenetics 1995; 5: 275-280.
9. Kukongviriyapan V, Lulitanond V, Areejitranusom C, Kongyingyose B, Laupattarakasem P. N-acetyltransferase polymorphism in Thailand. Hum Hered 1984; 34: 246-249.
10. Ong ML, Mant TG, Veerapen K, et al. The lack of relationship between acetylator phenotype and idiopathic systemic lupus erythematosus in a South-east Asian population: a study of Indians, Malays and Malaysian Chinese. Br J Rheumatol 1990; 29: 462-464.
11. Xie HG, Xu ZH, Ou Yang DS, et al. Meta-analysis of phenotype and genotype of NAT2 deficiency in Chinese populations. Pharmacogenetics 1997; 7: 503-514.
12. Lin HJ, Han CY, Lin BK. Slow acetylator mutations in the human polymorphic N-acetyltransferase gene in 786 Asians, Blacks, Hispanics, and Whites: Application to metabolic epidemiology. Am J Hum Genet 1993; 52: 827-834.
13. Yokoi T, Sawada M, Kamataki T. Polymorphic drug metabolism: studies with recombinant Chinese hamster cells and analyses in human populations. Pharmacogenetics 1995; 5(Suppl): 65-69.
14. Price Evans DA. An improved and simplified method of detecting the acetylator phenotype. J Med Genet 1969; 6: 405-407.
15. Varley H, Alan HG, Maurice B. Practical Clinical Biochemistry, 5th edn. Heinemann: London, 1976; 346-350.
16. Horai Y, Zhou HH, Zhang LM, Ishizaki T. N-acetylation phenotyping with dapsone in a mainland Chinese population. Br J Clin Pharmacol 1988; 25: 81-87.
17. Karim A, Elfellah M, Evans D. Human acetylator polymorphism: Estimate of allele frequency in Libya and details of global distribution. J Med Genet 1981; 18: 325-333.